

Celentyx Ltd News Release
11th May 2009



Ann Hayes Joins Celentyx Ltd as Chairman of the Board

BIRMINGHAM, UK – 11th May, 2009 - Celentyx Ltd, a pharmaceutical company with a focus on immune system mediated diseases, announced today that Dr Ann Hayes has been appointed as a Director and will Chair the Company's Board.

"Celentyx Ltd is truly at the forefront of immune disease research," says Dr Hayes. "I'm looking forward to working with the team as I believe that Celentyx's future holds tremendous potential".

Dr Hayes brings a wealth of industry expertise to Celentyx Ltd having worked for 22 years for GlaxoWellcome. Before the GSK merger, she was a Director in Drug Discovery, and was involved in long-term Discovery strategy, portfolio management and discovery project management.

Since leaving GSK in 2001, Dr Hayes has co-founded three companies, Ionix Pharmaceuticals Ltd, Therasci Ltd and Theradeas Ltd. In addition, Dr Hayes has sat on a number of boards, including Curidium Medica plc, Plethora Solutions plc and Sirius Ltd, and is a member of a number of advisory boards.

"We're delighted to bring Ann's invaluable experience to Celentyx," says Celentyx's CEO and Co-founder, Professor Nicholas Barnes. "She has been a vital part of a number of successful companies and we know she will help Celentyx to continue to grow as we embark on expanding both our drug development pipeline and our research services."

About Celentyx Ltd

Celentyx is a pharmaceutical company focused on developing treatments for diseases of the human immune system.

Using our proprietary Immuno-Profiling™ platform, Celentyx has developed a pipeline of reprofiled drug candidates and has created an increasing portfolio of valuable drug targets upon human immune cells relevant for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia).

Our discovery services enable partners to identify new development paths for clinical-stage drug candidates, facilitate lead candidate prioritisation or identify any potentially negative impact of a drug on the human immune system. The company has established partnerships with a number of medium and large pharmaceutical companies.

For more information, please visit Celentyx's website at www.celentyx.com or contact:
Catherine Brady, PhD
Commercial Manager
E-mail: catherine.brady@celentyx.com